Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year. If you're a growth investor, you probably ...

Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

Pfizer had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle. So last year the company created a phone line ...

Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022. By most standards, Pfizer looks like the ...

Pfizer isn't a great pick for growth investors, although its growth prospects are better than some might think. The stock is a good fit for value investors, though, with its low forward earnings ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

After learning doctors weren’t prescrbing its migraine drug Nurtec because they assumed insurance coverage would be a hassle, the company created a phone line for doctors and patients to call ...

Pfizer is currently a high-yield quality stock trading at reasonable valuations, indicating a margin of safety that surely curtails investment risks. With the stock market subject to bouts of ...

Pfizer PFE0.80%increase; green up pointing triangle had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle.

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine ...